JP2002535452A5 - - Google Patents

Download PDF

Info

Publication number
JP2002535452A5
JP2002535452A5 JP2000595660A JP2000595660A JP2002535452A5 JP 2002535452 A5 JP2002535452 A5 JP 2002535452A5 JP 2000595660 A JP2000595660 A JP 2000595660A JP 2000595660 A JP2000595660 A JP 2000595660A JP 2002535452 A5 JP2002535452 A5 JP 2002535452A5
Authority
JP
Japan
Prior art keywords
weight
hydrogel
polymerizable liquid
liquid mixture
weight percent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000595660A
Other languages
Japanese (ja)
Other versions
JP2002535452A (en
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2000/001664 external-priority patent/WO2000044356A1/en
Publication of JP2002535452A publication Critical patent/JP2002535452A/en
Publication of JP2002535452A5 publication Critical patent/JP2002535452A5/ja
Pending legal-status Critical Current

Links

Description

【特許請求の範囲】
【請求項1】
(a)コモノマーの少なくとも1種が親水性である約60重量パーセント〜約95重量パーセントの重合性コモノマーならびに十分な量の架橋剤及び該コモノマーと混和性である液体拡散強化剤を含有する重合性液体混合物を形成せしめて、約20%〜約85%の範囲内の平衡含水率(EWC)値を有する均質多孔性コポリマーを得;
ここで、重合性液体混合物はテトラヒドロフルフリルアルコール、シクロヘキシルアルコール、アセトン、エチレングリコールモノメチルエーテル、エチレングリコールモノエチルエーテル、エチレングリコールモノブチルエーテル、グリセリルイソプロピリデンエーテルジオキサン、テトラヒドロフラン、酢酸エチル及びジメチルスルホキシドよりなる群から選ばれる拡散強化剤を約1重量%〜約50重量%含有し;
(b)巨大分子の持続性放出のために有用な、均質多孔性コポリマーからなるヒドロゲルを形成せしめる
段階を含んでなる、薬剤の持続性送達のための均質多孔性ヒドロゲルの製造法。
【請求項2】
コモノマーが2−ヒドロキシエチルメタクリレート(HEMA)、N,N’−ジメチルアクリルアミド、メタクリル酸、アクリル酸、N−イソプロピルアクリルアミド、ビニルピロリドン、ヒドロキシプロピルメタクリレート及びアクリレートよりなる群から選ばれる少なくとも1種のモノマーを含んでなる請求項1に従う方法。
【請求項3】
重合性液体混合物が約75〜85%の範囲内のEWC値を有する均コポリマーを与える請求項1に従う方法。
【請求項4】
該製品をスピンキャスティングにより成形する請求項1に従う方法。
【請求項5】
重合性液体混合物が約0.1重量パーセント〜約5重量パーセントの架橋剤を含有する請求項1に従う方法。
【請求項6】
該架橋剤がエチレングリコールジメタクリレート及びトリメチロールプロパントリメタクリレートよりなる群から選ばれる請求項に従う方法。
【請求項7】
該重合性液体混合物がさらに紫外線開始剤を含んでなる請求項1に従う方法。
【請求項8】
紫外線開始剤がベンゾインメチルエーテルである請求項に従う方法。
【請求項9】
該重合性液体混合物がさらに還元剤−酸化剤重合触媒対を含んでなる請求項1に従う方法。
【請求項10】
該還元剤−酸化剤対が(a)ナトリウム及び過硫酸アンモニウムならびに(b)ナトリウム及び過硫酸カリウムより成る群から選ばれる請求項に従う方法。
【請求項11】
請求項1の方法に従って製造される製品。
【請求項12】
(a)活性薬剤及び場合により製薬学的に許容され得る担体を請求項1に従って製造されるヒドロゲルの溜の中に、活性薬剤の長期間の持続性放出を与えるのに十分な量で導入し;
(b)少なくとも1種の重合性液体モノマーを溜の上部の中に、溜を満たす量で導入し、該液体モノマーはその重合状態でカートリッジの平衡含水率値を越える平衡含水率値を有し;そして
(c)該モノマーを重合させて水−膨潤性、水−不溶性ポリマーの栓で溜の開口部を密閉し、あらかじめ決められた活性薬剤の放出を与える送達装置を形成せしめ
ことを含んでなる、装置からの活性薬剤の持続性放出のための送達装置の製造法。
【請求項13】
請求項12の方法に従って製造される送達装置。
【請求項14】
(a)2−ヒドロキシエチルメタクリレート(HEMA)を含んでなる約60重量パーセント〜約95重量パーセントのコモノマー、コモノマーと混和性である約10〜約50重量パーセントの液体拡散強化剤及び架橋剤を含有する重合性液体混合物を形成せしめ;
(b)重合性液体混合物を重合して、水に暴露した際に全体にわたり規則的な間隔で置かれた孔を有する均質コポリマーからなるヒドロゲルを形成するキセロゲルとなし、ここで該孔はそれぞれ直径が約10オングストローム〜約1.0ミ
クロンでありかつ液体拡散強化剤を含有し、該ヒドロゲルは35%〜約85%の範囲内の平衡含水率(EWC)値を有し、ここで該ヒドロゲルは溜を区画する均一な厚さの壁を有するカートリッジの形態であ
段階を含んでな、薬剤の持続性送達のための均質多孔性ヒドロゲル製品の製造法であって、該製品が最高で100,000の分子量を有する巨大分子の持続性放出のために有用である方法。
【請求項15】
該重合性液体混合物が約80重量パーセント〜約95重量パーセントのコモノマーを含有する請求項14に従う方法。
【請求項16】
コモノマーがさらにメタクリル酸及びN,N’−ジメチルアクリルアミドよりなる群から選ばれるコモノマーを含んでなる請求項14に従う方法。
【請求項17】
拡散強化剤が約20重量パーセント〜約40重量パーセントの量で存在する請求項14に従う方法。
【請求項18】
請求項14の方法に従って製造される製品。
【請求項19】
(a)活性薬剤及び場合により製薬学的に許容され得る担体を請求項14に従って製造されるヒドロゲルの溜の中に、活性薬剤の長期間の持続性放出を与えるのに十分な量で導入し;
(b)少なくとも1種の重合性液体モノマーを溜の上部の中に、溜を満たす量で導入し、該液体モノマーはその重合状態でカートリッジの平衡含水率値を越える平衡含水率値を有し;そして
(c)該モノマーを重合させて水−膨潤性、水−不溶性ポリマーの栓で溜の開口部を密閉し、あらかじめ決められた活性薬剤の放出を与える送達装置を形成せしめる
ことを含んでなる、装置からの活性薬剤の持続性放出のための送達装置の製造法。
【請求項20】
請求項19の方法に従って製造される送達装置。
【請求項21】
該重合性液体混合物が約60重量%のHEMA、約20重量%のジメチルアクリルアミド、及び約20重量%のイソプロピルアルコールを含んでなる拡散強化剤を含有する請求項14に従う方法。
【請求項22】
該重合性液体混合物が約77重量%のHEMA、約2重量%のメチルアクリルアミド及び約20重量%のポリエチレングリコールを含有する請求項14に従う方法。
【請求項23】
該重合性液体混合物が約80重量%のHEMA及び約20重量%のポリエチレングリコールを含んでなる拡散強化剤を含有する請求項14に従う方法。
【請求項24】
マトリックス全体にわたり規則的な間隔で置かれた孔を有する均質コポリマーマトリックスを含んでなり、ここで該孔はそれぞれ直径が約10オングストローム〜約1.0ミクロンでありかつ液体拡散強化剤を含有し、該液体拡散強化剤は水への暴露の前のヒドロゲルの合計重量の約10〜約50重量%を構成し、約35%〜約85%の範囲内の平衡含水率(EWC)を有するヒドロゲル。
【請求項25】
拡散強化剤が約10重量%〜約20重量%の量で存在する請求項24に従うヒドロゲル。
【請求項26】
該コポリマーマトリックスが水への暴露の前のヒドロゲルの合計重量の約60重量%の2−ヒドロキシエチルメタクリレート(HEMA)を含んでなり、該液体拡散強化剤が水への暴露の前のヒドロゲルの合計重量の約20重量%を構成し、ここで該ヒドロゲルが約35%〜約85%の範囲内の平衡含水率(EWC)を有する請求項24に従うヒドロゲル。
[Claims]
(1)
(A) from about 60 weight percent to about 95 weight percent of a polymerizable comonomer in which at least one of the comonomers is hydrophilic and a polymerizable comonomer containing a sufficient amount of a crosslinking agent and a liquid diffusion enhancer that is miscible with the comonomer; and allowed form a liquid mixture, to obtain a homogeneous porous copolymer has an equilibrium water content (EWC) value in the range of from about 20% to about 85%;
Here, the polymerizable liquid mixture is a group consisting of tetrahydrofurfuryl alcohol, cyclohexyl alcohol, acetone, ethylene glycol monomethyl ether, ethylene glycol monoethyl ether, ethylene glycol monobutyl ether, glyceryl isopropylidene ether dioxane, tetrahydrofuran, ethyl acetate, and dimethyl sulfoxide. About 1% to about 50% by weight of a diffusion enhancer selected from:
(B) A method of making a homogeneous porous hydrogel for sustained delivery of a drug, comprising the step of forming a hydrogel consisting of a homogeneous porous copolymer useful for sustained release of macromolecules.
(2)
At least one monomer selected from the group consisting of 2-hydroxyethyl methacrylate (HEMA), N, N'-dimethylacrylamide, methacrylic acid, acrylic acid, N-isopropylacrylamide, vinylpyrrolidone, hydroxypropyl methacrylate and acrylate; A method according to claim 1 comprising:
(3)
The method according to claim 1, the polymerizable liquid mixture gives uniform quality copolymer having a EWC value in the range of about 75% to 85%.
(4)
The method according to claim 1, wherein the product is formed by spin casting.
(5)
The method according to claim 1, wherein the polymerizable liquid mixture contains from about 0.1 weight percent to about 5 weight percent crosslinker.
6.
The method according to claim 5 , wherein said crosslinking agent is selected from the group consisting of ethylene glycol dimethacrylate and trimethylolpropane trimethacrylate.
7.
The method according to claim 1, wherein said polymerizable liquid mixture further comprises a UV initiator.
Claim 8.
The method according to claim 7 , wherein the UV initiator is benzoin methyl ether.
9.
The method according to claim 1, wherein the polymerizable liquid mixture further comprises a reducing agent-oxidizing agent polymerization catalyst pair.
10.
10. The method according to claim 9 , wherein said reducing agent-oxidizing agent pair is selected from the group consisting of (a) sodium and ammonium persulfate and (b) sodium and potassium persulfate.
11.
A product manufactured according to the method of claim 1.
12.
(A) in the reservoir of the active drug and optionally pharmaceutically acceptable carrier hydrogels in claim 1 thus produced, introduced in an amount sufficient to provide long term sustained release of the active agent And;
(B) introducing at least one polymerizable liquid monomer into the upper portion of the reservoir in an amount sufficient to fill the reservoir, the liquid monomer having an equilibrium water content value exceeding the equilibrium water content value of the cartridge in its polymerized state; ; and (c) the monomer is polymerized by water - swellable, water - sealing the opening of the reservoir with a plug of insoluble polymers, include Rukoto allowed forming a delivery device that provides the release of a predetermined active agent A method of making a delivery device for sustained release of an active agent from a device, comprising:
Claim 13
A delivery device manufactured according to the method of claim 12 .
14.
(A) comprising from about 60 weight percent to about 95 weight percent of a comonomer comprising 2-hydroxyethyl methacrylate (HEMA), and from about 10 to about 50 weight percent of a liquid diffusion enhancer and a crosslinker that is miscible with the comonomer. Forming a polymerizable liquid mixture,
(B) a xerogel which polymerizes the polymerizable liquid mixture to form a hydrogel consisting of a homogeneous copolymer having regularly spaced pores throughout when exposed to water, wherein the pores each have a diameter Is about 10 angstroms to about 1.0 mi
Containing Kron a is, liquid diffusing reinforcing agent, the hydrogel have a equilibrium water content (EWC) value in the range of from about 35% to about 85%, wherein the uniform thickness the hydrogel for partitioning reservoir ing include forms der Ru stage cartridge having a wall, a method of manufacturing a homogeneous porous hydrogel products for sustained delivery of drugs, huge the product has a molecular weight of up to 100,000 Methods that are useful for sustained release of molecules.
15.
15. The method according to claim 14, wherein said polymerizable liquid mixture contains from about 80 weight percent to about 95 weight percent comonomer.
16.
The method according to claim 14, wherein the comonomer further comprises a comonomer selected from the group consisting of methacrylic acid and N, N'-dimethylacrylamide.
17.
15. The method according to claim 14, wherein the diffusion enhancer is present in an amount from about 20 weight percent to about 40 weight percent.
18.
A product manufactured according to the method of claim 14.
(19)
(A) introducing the active agent and optionally a pharmaceutically acceptable carrier into the reservoir of the hydrogel prepared according to claim 14 in an amount sufficient to provide a long-term sustained release of the active agent. ;
(B) introducing at least one polymerizable liquid monomer into the upper portion of the reservoir in an amount sufficient to fill the reservoir, the liquid monomer having an equilibrium water content value exceeding the equilibrium water content value of the cartridge in its polymerized state; ; And
(C) polymerizing the monomer to seal the opening of the reservoir with a water-swellable, water-insoluble polymer stopper to form a delivery device that provides a predetermined release of the active agent.
A method of making a delivery device for sustained release of an active agent from a device, comprising:
20.
20. A delivery device manufactured according to the method of claim 19.
21.
The method according to claim 14, wherein the polymerizable liquid mixture comprises a diffusion enhancer comprising about 60% by weight HEMA, about 20% by weight dimethylacrylamide, and about 20% by weight isopropyl alcohol.
22.
15. The method according to claim 14, wherein said polymerizable liquid mixture contains about 77% by weight HEMA, about 2% by weight methylacrylamide and about 20% by weight polyethylene glycol.
23.
15. The method according to claim 14, wherein the polymerizable liquid mixture contains a diffusion enhancer comprising about 80% by weight HEMA and about 20% by weight polyethylene glycol.
24.
Ri Na contain homogeneous copolymer matrix having pores placed at regular intervals throughout the matrix, wherein the holes are each diameter of about 10 angstroms to about 1.0 microns and containing liquid diffusion reinforcing agents Wherein the liquid diffusion enhancer comprises from about 10 to about 50% by weight of the total weight of the hydrogel prior to exposure to water, and the hydrogel having an equilibrium water content (EWC) in the range of from about 35 % to about 85%. .
25.
25. The hydrogel according to claim 24 , wherein the diffusion enhancer is present in an amount from about 10% to about 20% by weight.
26.
Wherein the copolymer matrix comprises 2-hydroxyethyl methacrylate (HEMA) at about 60% by weight of the total weight of the hydrogel prior to exposure to water, and wherein the liquid diffusion enhancer comprises a sum of the hydrogels prior to exposure to water. 25. The hydrogel according to claim 24, comprising about 20% by weight of the hydrogel, wherein the hydrogel has an equilibrium water content (EWC) in the range of about 35% to about 85%.

JP2000595660A 1999-01-28 2000-01-26 Hydrogel compositions useful for sustained release of macromolecules and methods of making the same Pending JP2002535452A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11754699P 1999-01-28 1999-01-28
US60/117,546 1999-01-28
PCT/US2000/001664 WO2000044356A1 (en) 1999-01-28 2000-01-26 Hydrogel compositions useful for the sustained release of macromolecules and methods of making same

Publications (2)

Publication Number Publication Date
JP2002535452A JP2002535452A (en) 2002-10-22
JP2002535452A5 true JP2002535452A5 (en) 2007-03-08

Family

ID=22373509

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000595660A Pending JP2002535452A (en) 1999-01-28 2000-01-26 Hydrogel compositions useful for sustained release of macromolecules and methods of making the same

Country Status (11)

Country Link
US (1) US6361797B1 (en)
EP (1) EP1067911B1 (en)
JP (1) JP2002535452A (en)
AT (1) ATE407664T1 (en)
AU (1) AU757605B2 (en)
CA (1) CA2325386C (en)
DE (1) DE60040190D1 (en)
DK (1) DK1067911T3 (en)
ES (1) ES2313879T3 (en)
PT (1) PT1067911E (en)
WO (1) WO2000044356A1 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
DE10049297A1 (en) * 2000-10-04 2002-04-11 Basf Ag Water-soluble or water-dispersible (co) polymers of hydroxyalkyl (meth) acrylates, processes for their preparation and their use as coating agents, binders and / or film-forming auxiliaries in pharmaceutical dosage forms
US20020068078A1 (en) * 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
JP2005526879A (en) * 2002-03-11 2005-09-08 ファースト ウォーター リミテッド Absorbable hydrogel
US20060127878A1 (en) * 2002-12-18 2006-06-15 Salomon David H Hydrogel preparation and process of manufacture thereof
WO2004097504A1 (en) * 2003-04-24 2004-11-11 Ocular Sciences Inc. Hydrogel contact lenses and package systems and production methods for same
EP1773293B1 (en) 2004-06-17 2015-04-15 Endo Pharmaceuticals Solutions Inc. Compositions and methods for treating central precocious puberty
CA2581896C (en) 2004-09-29 2015-11-10 Mount Sinai School Of Medicine Of New York University Fsh and fsh receptor modulator compositions and methods for inhibiting osteoclastic bone resorption and bone loss in osteoporosis
US7759312B2 (en) * 2005-03-11 2010-07-20 Endo Pharmaceuticals Solutions Inc. Delivery of dry formulations of octreotide
EP2457564A1 (en) * 2005-03-11 2012-05-30 Endo Pharmaceuticals Solutions Inc. Controlled release formulations of octreotide
NZ543314A (en) * 2005-10-28 2007-08-31 Interag A delivery system where the driving substance contains the active component
MX2009011641A (en) * 2007-04-27 2010-03-04 Endo Pharmaceuticals Solutions Implant device release agents and methods of using same.
US8222015B2 (en) * 2007-05-11 2012-07-17 Toyota Motor Engineering & Manufacturing North America, Inc. Heat resistant bioactive composition
US8303536B2 (en) * 2007-08-30 2012-11-06 Sunstorm Research Corp. Implantable delivery device
WO2009158415A1 (en) * 2008-06-25 2009-12-30 Endo Pharmaceuticals Solutions Inc. Octreotide implant having a release agent
JP5622725B2 (en) 2008-06-25 2014-11-12 エンド ファーマスーティカルズ ソリューションズ インコーポレイテッド.Endo Pharmaceuticals Solutionsinc. Sustained delivery of exenatide and other polypeptides
EP2498764B1 (en) 2009-11-09 2017-09-06 Spotlight Technology Partners LLC Fragmented hydrogels
JP5864429B2 (en) 2009-11-09 2016-02-17 スポットライト テクノロジー パートナーズ エルエルシーSpotlight Technology Partners Llc Crosslinked hydrogel composition, method of forming hydrogel composition, and kit
US8329219B2 (en) 2009-12-22 2012-12-11 Cook Biotech Incorporated Methods for producing ECM-based biomaterials
US20150164117A1 (en) * 2012-07-13 2015-06-18 Tufts University Encapsulation of fragrance and/or flavors in silk fibroin biomaterials
CN105209074A (en) 2012-10-20 2015-12-30 得克萨斯大学体系董事会 Cancer cell trap
US10098839B2 (en) 2014-03-20 2018-10-16 The Regents Of The University Of California Hydrogel toxin-absorbing or binding nanoparticles
US11661439B2 (en) 2017-12-17 2023-05-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Peptide hydrogels and use thereof
EP3791858A1 (en) * 2019-09-13 2021-03-17 UPM-Kymmene Corporation Injectable pharmaceutical formulation
EP3791864A1 (en) 2019-09-13 2021-03-17 UPM-Kymmene Corporation Method for preparing pharmaceutical composition and pharmaceutical composition

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4298002A (en) * 1979-09-10 1981-11-03 National Patent Development Corporation Porous hydrophilic materials, chambers therefrom, and devices comprising such chambers and biologically active tissue and methods of preparation
US4959217A (en) * 1986-05-22 1990-09-25 Syntex (U.S.A.) Inc. Delayed/sustained release of macromolecules
US4954587A (en) * 1988-07-05 1990-09-04 Ciba-Geigy Corporation Dimethylacrylamide-copolymer hydrogels with high oxygen permeability
AU618817B2 (en) * 1988-07-05 1992-01-09 Novartis Ag Dimethylacrylamide-copolymer hydrogels with high oxygen permeability
DK0550641T3 (en) * 1990-09-28 1994-08-22 Pfizer Dispensing device containing a hydrophobic medium
US5266325A (en) * 1990-09-28 1993-11-30 Hydro Med Science Division Of National Patent Development Corp. Preparation of homogeneous hydrogel copolymers
AU651654B2 (en) * 1992-01-14 1994-07-28 Endo Pharmaceuticals Solutions Inc. Manufacture of water-swellable hydrophilic articles and drug delivery devices
JPH04202201A (en) * 1990-11-29 1992-07-23 Mitsui Toatsu Chem Inc Production of porous copolymer
JP2530079B2 (en) * 1992-02-05 1996-09-04 ナショナル・パテント・ディベロプメント・コーポレーション Manufacture of water-swellable hydrophilic products and drug release devices

Similar Documents

Publication Publication Date Title
JP2002535452A5 (en)
CA2325386A1 (en) Hydrogel compositions useful for the sustained release of macromolecules and methods of making same
Scott et al. Highly crosslinked, PEG-containing copolymers for sustained solute delivery
US3607848A (en) Method for preparing insoluble,cross-linked organic hydrogels comprising copolymers of glycol monoesters with diesters
Lowman et al. Analysis of the complexation/decomplexation phenomena in graft copolymer networks
CA1086898A (en) Hydrophilic gel polymer
Yanfeng et al. Swelling kinetics and stimuli-responsiveness of poly (DMAEMA) hydrogels prepared by UV-irradiation
Park et al. Thermally induced core‐shell type hydrogel beads having interpenetrating polymer network (IPN) structure
Mullarney et al. Drug diffusion in hydrophobically modified N, N-dimethylacrylamide hydrogels
Serra et al. Drug transport mechanisms and release kinetics from molecularly designed poly (acrylic acid-g-ethylene glycol) hydrogels
Podual et al. Preparation and dynamic response of cationic copolymer hydrogels containing glucose oxidase
Takemoto et al. Fabrication of surface-modified hydrogels with polyion complex for controlled release
WO2003093327A1 (en) Gel having multiple network structure and method for preparation thereof
SE461502B (en) COMPOSITION FOR REGULATED RELEASE OF A WATER-SOLUBLE MEDICINE FROM A MICROPHASE-STORED HYDROGEL
Fundueanu et al. Poly (vinyl alcohol) microspheres with pH-and thermosensitive properties as temperature-controlled drug delivery
HN1994001403A (en) POLYMER FOR OPHTHALMOLOGICAL LENSES INCORPORATED IN A CYCLIC MONOMER
Gulsen et al. Effect of water content on transparency, swelling, lidocaine diffusion in p-HEMA gels
Ali et al. Evaluation of cross-linked hydroxypropyl methylcellulose graft-methacrylic acid copolymer as extended release oral drug carrier
EP1773893B1 (en) Polymer having interconnected pores for drug delivery and method
Wang et al. A novel method to enhance the stability of alginate-poly-L-lysine-alginate microcapsules
CN108003266B (en) A kind of quadruple stimuli responsive polyaminoacid nanogel and its preparation method and application
Wen et al. Microcapsules through polymer complexation: I: Complex coacervation of polymers containing a high charge density
TWI698453B (en) Anti-blue light material and preparation method thereof
Kureha et al. Nanoscale structures of poly (oligo ethylene glycol methyl ether methacrylate) hydrogels revealed by small-angle neutron scattering
Siddiqa et al. Preparation of letrozole dispersed pHEMA/AAm-g-LDPE drug release system: In-vitro release kinetics for the treatment of endometriosis